| abstract |
Use of an agent capable of inhibiting the interaction between SIRP1α and CD47, in the preparation of a composition for the inhibition of macrophage involvement in autoimmune disease. The invention further relates to a method for the treatment of an autoimmune disease with macrophage involvement, comprising administering to a mammal an effective amount of an agent which inhibits the interaction between CD47 and SIRP1α. The invention also relates to a method for identifying an agent capable of inhibiting the interaction between CD47 and SIRP1α, comprising the steps of exposing one or more test compounds to CD47 and/or SIRP1α, and monitoring the ability of the test compound to inhibit their interaction. |